Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

35.00
+0.33000.95%
Post-market: 35.000.00000.00%16:13 EDT
Volume:1.85M
Turnover:64.18M
Market Cap:6.07B
PE:-16.20
High:35.21
Open:34.61
Low:34.11
Close:34.67
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:1.31
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:12.99
PE(LYR):-13.72

Loading ...

A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026

Simply Wall St.
·
Apr 27

Cogent Biosciences announces annual shareholder meeting

Reuters
·
Apr 24

Cogent says Phase 3 PEAK trial meets endpoint for bezuclastinib plus sunitinib in GIST

Reuters
·
Apr 21

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 Peak Trial in Gastrointestinal Stromal Tumors (Gist) at the 2026 American Society of Clinical Oncology (Asco) Annual Meeting

THOMSON REUTERS
·
Apr 21

Lexicon COGT reports Q1 EPS $2.07, consensus $1.74

TIPRANKS
·
Apr 17

Cogent presents preclinical data on KRAS inhibitor CGT1263 at AACR 2026

Reuters
·
Apr 17

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (Aacr) Annual Meeting 2026

THOMSON REUTERS
·
Apr 17

Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Apr 11

Cogent Biosciences submits bezuclastinib new drug application to the FDA

TIPRANKS
·
Apr 01

Cogent submits FDA NDA for bezuclastinib in second-line GIST under RTOR program

Reuters
·
Apr 01

Fairmount Funds Management disposes of USD 243M Cogent Biosciences common shares

Reuters
·
Apr 01

LifeSci Capital Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Mar 21

Cogent Biosciences Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Cogent Biosciences assumed with a Buy at Jefferies

TIPRANKS
·
Mar 16

BUZZ-Cogent Biosciences rises after US FDA agrees to review rare‑disease drug

Reuters
·
Mar 16

Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)

Reuters
·
Mar 16

Cogent Biosciences Shares Rise 7.2% Premarket After FDA Accepts Application to Review Rare Disease Drug

THOMSON REUTERS
·
Mar 16

Cogent Biosciences: Bezuclastinib Pdufa Target Action Date Set for Dec 30, 2026

THOMSON REUTERS
·
Mar 16